1-3 of 3
Changping Wu
Close
Sort by
Journal Articles

Rituximab-Based Regimen As First-Line Treatment in Chinese Patients with Follicular Lymphoma: Three-Year Safety Data from a Prospective, Observational Study

Jianqiu Wu, Yongping Song, Liping Su, Mingzhi Zhang, Wei Li, Yu Hu, MD PhD, Xiaohong Zhang, Yuhuan Gao, Zuoxing Niu, Ru Feng, MD, Wei Wang, Jiewen Peng, Xiaolin Li, Xuenong Ouyang, Changping Wu, Weijing Zhang, Yun Zeng, Zhen Xiao, Yingmin Liang, Yongzhi Zhuang, Jishi Wang, PhD, Zimin Sun, Hai Bai, Tongjian Cui, Jifeng Feng
Journal: Blood
Blood (2017) 130 (Supplement 1): 5167.
https://doi.org/10.1182/blood.V130.Suppl_1.5167.5167
Published: 2017
Journal Articles

The Incidence of HBV Reactivation in Patients Receiving First-Line R-CHOP Chemotherapy: Three-Year Follow-up Results from a Prospective, Observational Study

Jianqiu Wu, Yongping Song, Liping Su, Mingzhi Zhang, Wei Li, Yu Hu, MD PhD, Xiaohong Zhang, Yuhuan Gao, Zuoxing Niu, Ru Feng, MD, Wei Wang, Jiewen Peng, Xuenong Ouyang, Xiaolin Li, Changping Wu, Weijing Zhang, Yun Zeng, Zhen Xiao, Yingmin Liang, Yongzhi Zhuang, Jishi Wang, PhD, Zimin Sun, Hai Bai, Tongjian Cui, Jifeng Feng
Journal: Blood
Blood (2017) 130 (Supplement 1): 5213.
https://doi.org/10.1182/blood.V130.Suppl_1.5213.5213
Published: 2017
Journal Articles

Three-Year Follow-up on Safety and Effectiveness of Rituximab Plus Chemotherapy As First-Line Treatment of Diffuse Large B-Cell Lymphoma

Jifeng Feng, Jianqiu Wu, Yongping Song, Liping Su, Mingzhi Zhang, Wei Li, Yu Hu, MD PhD, Xiaohong Zhang, Yuhuan Gao, Zuoxing Niu, Ru Feng, MD, Wei Wang, Jiewen Peng, Xiaolin Li, Xuenong Ouyang, Changping Wu, Weijing Zhang, Yun Zeng, Zhen Xiao, Yingmin Liang, Yongzhi Zhuang, Jishi Wang, PhD, Zimin Sun, Hai Bai, Tongjian Cui
Journal: Blood
Blood (2017) 130 (Supplement 1): 5208.
https://doi.org/10.1182/blood.V130.Suppl_1.5208.5208
Published: 2017